CA-TREASURE-DATA
8.10.2020 14:02:14 CEST | Business Wire | Press release
Treasure Data ™ today unveiled its Global Partner Program , offering agencies, consultancies, technology service providers, independent software vendors (ISVs) and data specialists new certifications, training, and technical, marketing and sales support for the Company’s market-leading Customer Data Platform (CDP). The program will be launching with 20 strategically selected partners and is set to grow as we continue to expand our customer base in all territories.
“Enterprises are turning to trusted partners in their respective industries to accelerate customer-centric digital transformation and solve complex data, scale and other obstacles that hinder exceptional brand experiences,” said Stephen Lee, Vice President of Strategy and Business Development, Treasure Data. “Treasure Data’s Global Partner Program helps trusted enterprise partners expand their CDP technical acumen and experience to grow their market and revenue opportunities.”
Certified Partners help customers throughout their entire CDP deployment journey. For agencies, and consultancies, the program offers three tiers—bronze, silver and gold—with level-specific commitments for online training, joint marketing, market development funds (MDF), discounts, and technical and sales support. In addition to access to Treasure Data’s CDP Academy training, partners may also receive additional certified sales and technical training matched to key roles ranging from sales and marketing operations to data architects and scientists. The program is also open to select Treasure Data technology partners.
“Acxiom and its partners strive to drive transformational change for clients through strategic partnerships and we’re excited to be working with such a powerful tool as the Treasure Data CDP,” says Mike Menzer, President, Acxiom International. “Customer Data Platforms are creating a lot of growth right now and we see the Acxiom and Treasure Data combination as a key solution to driving value for our clients.”
“CDPs like Treasure Data are playing an increasingly important role in helping marketers better understand who their customers are,” says Jayne Babine, Executive Vice President, Partnerships and Sales at MightyHive. “As one of the leading full-service global marketing services firms, MightyHive is thrilled to be partnering with Treasure Data to make our clients more successful around data marketing strategy and execution.”
Treasure Data’s CDP unifies and unlocks the full potential of customer data. It captures all online and offline customer interactions as they happen, helping companies to understand all brand interactions with the precise detail needed to engage customers at the right time in the right place. Trusted by more than 400 organizations worldwide, Treasure Data provides an enterprise-scale, independent solution that lets partners work with any existing technology stack and gives them the flexibility to ingest all types of data. This makes it easy to integrate the Treasure Data CDP with partner offerings and preferred solutions stacks to accelerate the delivery of outstanding, personalized data-driven brand experiences.
Partners included in Treasure Data’s Global Partner Program: Accenture, Acxiom, MightyHive in the Gold Tier. Allant, BitBang, Brain+Trust Partners, Merkle (Isobar, Sokrati) Search Discovery, SilverBullet in the Silver Tier. AdGlobal360, Ansira, Exostatic, Gravitai, Green Lyzard, HGS Digital, Hero Digital, Hexagon Data, Keyrus, Verticurl in the Bronze Tier. For more information on our partner program, please visit https://www.treasuredata.com/partnerships/
About Treasure Data
Treasure Data Customer Data Platform (CDP) empowers enterprises by delivering rich insights that drive outstanding customer experiences. Built on a strong data management foundation, our CDP enables brands to securely unify customer data across silos at scale so they can better identify, engage and acquire customers. The highly configurable platform boasts a comprehensive connector network that evolves with your existing technology stack to future-proof all customer data initiatives. Treasure Data has more than 400 customers including Fortune 500 and Global 2000 enterprises, and is a wholly-owned subsidiary of Arm Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005078/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom